— Know what they know.
Not Investment Advice

SYK vs MDT vs ABT

161 measures in 16 categories, one definition each, computed from filings and market data.
SYK73.6
Stryker Corporation
Healthcare · Medical - Devices
$294.66 +0.49%$113.0B mkt cap
Score DNA
MDT63.6
Medtronic Plc
Healthcare · Medical - Devices
$94.75 −0.73%$121.2B mkt cap
Score DNA
ABT56.6
Abbott Laboratories
Healthcare · Medical - Devices
$104.88 +0.20%$181.5B mkt cap
Score DNA

Price, rebased to 100 three years ago

SYK   MDT   ABT   · weekly adjusted closes
100120140160Jan 24Apr 24Jul 24Oct 24Jan 25Apr 25Jul 25Oct 25Jan 26Apr 26Jul 26Oct 26MDT 145ABT 120SYK 116
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.

Smart money

8 measures
MeasureSYKMDTABT
Insider open-market buys, 180d 0 0 3
Insider $ bought, 180d — — $1.30M
Congress purchases, 180d 1 2 13
Last Congress purchase 2026-09-04 2026-09-11 2026-09-18
13F net change in holders −37 −94 −134
ETFs adding shares, 30d 1,328 567 1,517
ETFs trimming, 30d 980 485 1,197
Net ETF funds, 30d +348 +82 +320

Valuation

16 measures
MeasureSYKMDTABT
P/E (TTM) 30.3x
56th
23.2x
41st
33.5x
67th
PEG (P/E ÷ 3-yr EPS CAGR) 2.75
80th
1.60
60th
18.41
100th
Price / sales 4.4x
72nd
3.2x
48th
3.9x
62nd
Price / book 4.7x
62nd
2.4x
36th
3.6x
54th
Price / tangible book — — —
Price / free cash flow 24.0x
44th
19.8x
36th
20.8x
39th
Price / operating cash flow 20.5x
53rd
15.1x
28th
18.3x
40th
Enterprise value $124.5B
97th
$140.5B
98th
$208.5B
100th
EV / sales 4.8x
73rd
3.7x
57th
4.5x
65th
EV / EBITDA 18.6x
50th
13.8x
42nd
19.0x
53rd
EV / EBIT 22.9x
45th
19.2x
33rd
26.1x
58th
EV / free cash flow 26.5x
47th
22.9x
36th
23.9x
39th
Earnings yield 3.3%
75th
4.3%
82nd
3.0%
70th
FCF yield 4.2%
73rd
5.1%
78th
4.8%
77th
Operating cash flow yield 4.9%
62nd
6.6%
80th
5.5%
72nd
Graham number (per share) $116.22
93rd
$59.83
74th
$45.32
56th

Profitability (TTM)

12 measures
MeasureSYKMDTABT
Gross margin 65.2%
52nd
66.7%
57th
56.8%
38th
EBITDA margin 25.9%
87th
27.1%
90th
23.5%
82nd
Operating margin 22.0%
93rd
18.1%
85th
17.0%
83rd
EBIT margin 21.1%
88th
19.5%
85th
17.2%
82nd
Net margin 14.4%
87th
13.9%
85th
11.6%
80th
NOPAT margin 16.0%
85th
14.4%
82nd
12.3%
73rd
FCF margin 18.2%
83rd
16.3%
80th
18.7%
88th
Operating cash flow margin 21.4%
85th
21.4%
87th
21.3%
83rd
R&D / revenue 6.4%
31st
7.8%
39th
6.8%
34th
SG&A / revenue 34.0%
27th
32.4%
18th
28.9%
15th
Stock comp / revenue 1.0%
15th
1.3%
23rd
1.5%
30th
Effective tax rate 27.6%
88th
20.2%
19th
27.8%
90th

Returns on capital

11 measures
MeasureSYKMDTABT
ROE (on average equity) 16.5%
86th
10.7%
69th
10.7%
71st
ROA 7.9%
80th
5.7%
72nd
5.6%
70th
ROIC 11.6%
73rd
7.8%
66th
7.3%
63rd
ROCE 13.2%
87th
9.0%
72nd
8.8%
70th
Return on tangible assets 11.6%
87th
8.0%
70th
8.3%
73rd
Cash ROIC (OCF / invested capital) 15.6%
69th
11.6%
61st
12.7%
68th
Gross profitability (GP / assets) 35.1%
47th
26.8%
33rd
24.2%
22nd
ROIC, 3-yr average 8.7%
73rd
6.0%
65th
10.8%
80th
ROIC, 5-yr average 10.0%
71st
6.7%
65th
13.9%
82nd
ROE, 5-yr average 15.1%
81st
9.1%
73rd
17.9%
85th
Incremental ROIC 328.7%
92nd
90.1%
84th
-22.2%
33rd

Growth

17 measures
MeasureSYKMDTABT
Revenue growth (TTM YoY) 8.5%
39th
9.8%
45th
8.1%
38th
Revenue growth (QoQ) 9.5%
58th
-0.5%
13th
12.8%
70th
Revenue CAGR, 3 yr 9.9%
43rd
6.0%
28th
5.0%
23rd
Revenue CAGR, 5 yr 9.7%
38th
3.5%
15th
3.0%
12th
Gross profit CAGR, 3 yr 13.1%
56th
6.5%
29th
9.9%
38th
Operating income CAGR, 3 yr 12.8%
52nd
6.4%
32nd
9.4%
40th
Net income growth (TTM YoY) 27.8%
62nd
12.2%
58th
-61.2%
8th
Net income CAGR, 3 yr 11.2%
45th
13.1%
50th
1.7%
30th
EPS growth (TTM YoY) 27.9%
62nd
12.4%
58th
-61.0%
8th
EPS CAGR, 3 yr 11.0%
35th
14.5%
50th
1.8%
25th
EPS CAGR, 5 yr 12.1%
65th
7.3%
45th
-2.6%
20th
FCF growth (TTM YoY) 16.8%
50th
15.6%
47th
28.7%
57th
FCF CAGR, 3 yr 24.8%
42nd
11.3%
19th
16.7%
31st
Operating cash flow CAGR, 3 yr 22.2%
58th
11.3%
39th
9.9%
32nd
Book value CAGR, 3 yr 11.2%
63rd
0.6%
37th
11.3%
67th
Dividend CAGR, 3 yr 1.5%
12th
1.7%
25th
2.5%
50th
Sustainable growth rate 10.7%
48th
3.2%
15th
2.3%
4th

Margin history & stability

7 measures
MeasureSYKMDTABT
Gross margin, 3-yr average 62.9%
45th
65.1%
51st
53.4%
26th
Operating margin, 3-yr average 22.0%
94th
17.3%
89th
16.9%
87th
Net margin, 3-yr average 14.3%
87th
13.2%
85th
19.2%
94th
FCF margin, 3-yr average 16.1%
89th
15.9%
87th
16.1%
91st
Revenue stability (0-1) 0.99
92nd
0.73
21st
0.69
17th
Earnings stability (0-1) 0.81
85th
0.17
32nd
0.04
6th
Margin stability (0-1) 0.97
68th
0.98
89th
0.95
40th

Liquidity (latest quarter)

7 measures
MeasureSYKMDTABT
Cash & short-term investments $3.5B
95th
$8.8B
100th
$5.6B
98th
Net cash (− = net debt) −$11.5B
5th
−$19.3B
2nd
−$27.0B
0th
Working capital $7.7B
98th
$12.6B
100th
$6.7B
97th
Current ratio 2.16
33rd
2.07
30th
1.38
8th
Quick ratio 1.33
27th
2.09
45th
0.97
12th
Cash ratio (cash + ST investments / current liabilities) 0.52
30th
0.75
43rd
0.31
22nd
Defensive interval (days) 236 days
27th
181 days
17th
279 days
43rd

Leverage & solvency (latest quarter)

13 measures
MeasureSYKMDTABT
Total debt $14.9B
97th
$28.2B
98th
$32.6B
100th
Debt / equity 0.62
56th
0.56
53rd
0.64
58th
Net debt / equity 0.48
60th
0.38
58th
0.53
65th
Debt / assets 31.2%
58th
30.2%
57th
29.9%
53rd
Debt / capital 38.4%
56th
35.9%
53rd
38.9%
58th
Debt / EBITDA 2.23
45th
2.77
53rd
2.98
58th
Net debt / EBITDA 1.71
45th
1.90
47th
2.46
58th
Interest coverage (EBIT / interest) 6.6x
77th
10.1x
81st
12.6x
87th
Cash interest coverage 6.7x
71st
11.1x
83rd
15.5x
90th
Debt payback (years of OCF) 2.7 yrs
40th
3.5 yrs
51st
3.3 yrs
49th
Liabilities / assets 50.0%
53rd
45.5%
45th
52.6%
57th
IS credit model rating AA- AA- A+
Implied credit spread (bps) 100
22nd
100
22nd
125
28th

Efficiency

11 measures
MeasureSYKMDTABT
Asset turnover 0.55
37th
0.41
15th
0.48
23rd
Fixed asset turnover 5.77
64th
— 3.64
24th
Inventory turnover 1.7
41st
— 2.8
78th
Receivables turnover 6.7
62nd
11.6
100th
5.6
32nd
Days sales outstanding 54 days
38th
32 days
0th
65 days
68th
Days inventory outstanding 219 days
59th
— 129 days
22nd
Days payables outstanding 63 days
57th
77 days
68th
83 days
75th
Cash conversion cycle (days) 210 days
48th
−54 days
3rd
112 days
20th
Capex / revenue 3.2%
45th
5.1%
69th
2.5%
29th
Capex / depreciation 0.66
48th
0.67
50th
0.40
21st
Operating expense ratio 43.1%
19th
46.9%
25th
43.8%
20th

Cash flow & earnings quality

7 measures
MeasureSYKMDTABT
Operating cash flow / net income 1.48
41st
1.54
44th
1.83
70th
FCF / net income 1.26
48th
1.17
44th
1.61
78th
FCF / operating cash flow 85.1%
76th
76.3%
62nd
88.0%
83rd
Capex / operating cash flow 14.9%
24th
23.7%
38th
12.0%
17th
Accruals ratio -3.8%
68th
-3.0%
72nd
-4.6%
52nd
Sloan accruals ratio 1.6%
68th
-2.1%
45th
-7.5%
25th
Earnings quality score (0-1) 1.00
48th
1.00
48th
1.00
48th

Dividends & buybacks

9 measures
MeasureSYKMDTABT
Dividend yield 1.2%
93rd
3.0%
100th
2.4%
97th
Dividend per share (TTM) $3.52
100th
$2.86
98th
$2.52
97th
Payout ratio (dividends / net income) 35.3%
85th
69.8%
96th
78.5%
100th
Dividends / FCF 28.0%
83rd
59.5%
97th
48.9%
89th
Dividend growth (YoY) 5.4%
56th
1.5%
33rd
7.7%
67th
Buyback yield 0.1%
65th
1.0%
72nd
1.0%
73rd
Shareholder yield (dividends + buybacks) 1.3%
70th
4.0%
95th
3.4%
87th
Share count change (YoY) -0.1%
36th
-0.2%
34th
-0.5%
32nd
Buybacks, last 5 years $822.0M
78th
$4.9B
98th
$5.8B
100th

Scores & forensic checks

15 measures
MeasureSYKMDTABT
IS score 74
93rd
64
80th
57
67th
IS profitability 72
95th
57
80th
46
63rd
IS growth 64
59th
55
41st
28
11th
IS value 52
77th
64
88th
49
72nd
IS momentum 90
86th
83
77th
60
32nd
IS risk (safety) 100
62nd
65
42nd
80
52nd
IS quality 87
95th
83
88th
70
62nd
IS balance sheet 63
67th
70
72nd
62
65th
IS earnings quality 78
93rd
93
100th
72
72nd
IS cash flow 70
77th
66
75th
74
82nd
Piotroski F-score (0-9) 9
95th
9
95th
5
35th
Altman Z-score 4.8
63rd
2.9
47th
3.0
52nd
Beneish M-score −2.74
30th
−3.44
7th
−2.69
41st
Ohlson O-score −9.18
22nd
−9.52
13th
−8.73
28th
IS credit score 81
78th
81
77th
76
72nd

Per share

7 measures
MeasureSYKMDTABT
EPS, diluted (TTM) $9.66
100th
$4.07
87th
$3.11
75th
Book value per share $62.15
95th
$39.09
88th
$29.32
82nd
Tangible book per share −$3.49
13th
−$2.01
18th
−$0.40
28th
Revenue per share $66.94
95th
$29.21
77th
$26.73
73rd
FCF per share $12.18
97th
$4.77
83rd
$5.00
85th
Operating cash flow per share $14.31
97th
$6.25
83rd
$5.68
78th
Cash per share $9.01
87th
$6.86
80th
$3.21
57th

Size (TTM)

8 measures
MeasureSYKMDTABT
Market cap $113.0B
97th
$121.2B
98th
$181.5B
100th
Revenue $25.8B
97th
$37.5B
98th
$46.6B
100th
EBITDA $6.7B
97th
$10.2B
98th
$11.0B
100th
Net income $3.7B
97th
$5.2B
98th
$5.4B
100th
Free cash flow $4.7B
97th
$6.1B
98th
$8.7B
100th
Total assets $47.9B
97th
$93.3B
98th
$109.2B
100th
Shareholders' equity $24.0B
95th
$50.2B
98th
$51.1B
100th
Employees 56,000
95th
95,000
98th
115,000
100th

Price performance

9 measures
MeasureSYKMDTABT
1 day +0.5% −0.7% +0.2%
1 week +6.3% +7.1% +6.0%
1 month +5.5% +3.0% +2.6%
3 months −7.7% +14.7% +3.2%
6 months −14.2% +11.8% +8.3%
Year to date −15.4% +1.2% −15.1%
1 year −20.3% +2.7% −19.0%
3 years, cumulative +15.4% +43.4% +18.3%
5 years, cumulative +16.5% −11.2% −4.1%

Technicals

4 measures
MeasureSYKMDTABT
RSI 14 58.9 64.6 59.5
From 52-week high −24.9% −7.9% −20.6%
From 52-week low +10.4% +31.5% +28.0%
Beta 0.78 0.57 0.58
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms